Literature DB >> 2546277

The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma.

S Béguin1, J Mardiguian, T Lindhout, H C Hemker.   

Abstract

We studied the mode of action of the low molecular weight heparin PK10169 and two of its constituent fractions: EMT 966 High Molecular Weight Fraction and EMT 967 Low Molecular Weight Fraction. EMT 966 like standard heparin, acts primarily on thrombin formed and not on prothrombinase (S type heparin). In contrast EMT 967 has no direct effect on thrombin. At high concentrations, it inhibits the prothrombinase complex (P type heparin). PK10169, that contains the two EMTs shows both activities: antithrombin and antiprothrombinase (mixed type heparin). The addition of increasing amounts of EMT 967 to a constant amount of EMT 966 does not influence the breakdown constant of endogenous thrombin which is determined by the concentration of EMT 966 only. This demonstrates the absence of competition for AT III between the two components of PK10169. In platelet rich plasma, EMT 966 inhibits and postpones thrombin generation more efficiently than unfractionated heparin, probably because it is less sensitive to neutralization by platelet components (platelet factor 4). Amounts of EMT 967 that hardly inhibit thrombin generation in platelet rich plasma enhance the effect of EMT 966 probably by neutralizing platelet factor 4.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546277

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.

Authors:  P J Zed
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 2.  Low molecular weight heparins and coronary artery disease.

Authors:  P J Zed
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.

Authors:  F A Spencer; S P Ball; Q Zhang; L Liu; S Benoit; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.

Authors:  Ewa Orlewska; Andrzej Budaj; Dariusz Tereszkowski-Kaminski
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 5.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Heparins: A Shift of Paradigm.

Authors:  H Coenraad Hemker; Raed Al Dieri; Suzette Béguin
Journal:  Front Med (Lausanne)       Date:  2019-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.